Five Prime Therapeutics Inc (FPRX) 24.07 $FPRX Five

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2015 at 10:33 PM

Five Prime Therapeutics Inc (FPRX) 24.07 $FPRX

Five Prime Therapeutics to Host Research & Development Day on May 5, 2015
GlobeNewswire - Wed Apr 22, 3:05PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that the company will hold its first Research & Development Day event for the institutional investment community in New York City on May 5, 2015. The formal program and webcast will begin at 8:30 am ET and will conclude at approximately 11:45 am ET.
FPRX: 24.07 (-0.85)

Is Immuno-Oncology the Best Area of Biotech to Invest in Right Now?
George Budwell, The Motley Fool - Motley Fool - Wed Apr 22, 7:11AM CDT
Biotechnology is rapidly giving rise to ground-breaking new medicines that are dramatically changing the outlook for devastating diseases such as hepatitis C, malaria, and, perhaps most astoundingly, cancer. This innovation boom has gone hand in hand...
AGEN: 6.08 (+0.21), ADXS: 22.18 (+0.10), PFE: 34.93 (+0.04), MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), BMY: 66.60 (-0.21), FPRX: 24.07 (-0.85)

Nasdaq stocks posting largest percentage increases
AP - Fri Apr 17, 5:13PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
FATE: 6.29 (-0.10), MAT: 28.36 (+1.14), CHKE: 22.82 (-0.17), TGLS: 11.98 (+0.70), FPRX: 24.07 (-0.85)

After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 4:38PM CDT

VSTM: 9.99 (unch), NBL: 51.18 (+0.05), SIGM: 8.36 (+0.29), ARGS: 8.48 (-0.11), IBN: 10.30 (+0.12), ERI: 7.50 (+0.30), SGMS: 12.48 (+0.25), BNDX: 53.90 (-0.10), BIND: 7.01 (-0.30), FPRX: 24.07 (-0.85)

Cancer PD-1 inhibitor market only half as large as consensus says analyst
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 11:37AM CDT

MDVN: 128.88 (+0.29), AZN: 73.35 (+0.65), MRK: 57.69 (+0.03), BMY: 66.60 (-0.21), SRNE: 10.36 (-0.43), CELG: 115.54 (+0.72), FPRX: 24.07 (-0.85)

'Mad Money' Lightning Round: Buy, Buy, Buy ConocoPhillips
at The Street - Thu Mar 26, 5:00AM CDT
Cramer likes Ryanair, Pfizer and MeadWestvaco but is avoiding Rovi Corporation, Five Prime Therapeutics and Avon Products.
RYAAY: 66.62 (-0.12), AVP: 8.81 (-0.07), ISIS: 66.26 (-0.03), MWV: 47.23 (+0.53), PFE: 34.93 (+0.04), IP: 53.04 (+0.52), COP: 67.88 (-0.14), VG: 4.91 (-0.05), URI: 95.79 (-2.11), ROVI: 19.46 (+0.10), FPRX: 24.07 (-0.85)

Pfizer Is An Outright Buy - Cramer's Lightning Round (3/25/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Thu Mar 26, 3:55AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, March 25. Bullish Calls: Isis Pharmaceuticals (NASDAQ: ISIS ): "My take is this: It is going to go even lower because it's part of the highest...
AVP: 8.81 (-0.07), PFE: 34.93 (+0.04), IP: 53.04 (+0.52), COP: 67.88 (-0.14), PCLN: 1,212.90 (+18.64), VG: 4.91 (-0.05), NFLX: 557.68 (-2.76), RYAAY: 66.62 (-0.12), ISIS: 66.26 (-0.03), MWV: 47.23 (+0.53), FPRX: 24.07 (-0.85), ROVI: 19.46 (+0.10), URI: 95.79 (-2.11)

Jim Cramer's 'Mad Money' Recap: This Market Has Gotten Too Hot
at The Street - Wed Mar 25, 7:13PM CDT
As Cramer predicted, biotechs have started to cool. What should investors do next? Nothing, he advises.
72.52 (+0.43), UTX: 116.96 (+0.01), KRFT: 88.25 (-0.22), PAH: 27.81 (+0.19), INTC: 32.70 (+0.27), PVH: 103.33 (-0.39), VG: 4.91 (-0.05), DFS: 57.89 (-1.37), RYAAY: 66.62 (-0.12), PAYX: 49.28 (+0.22), SONC: 30.75 (+0.14), MWV: 47.23 (+0.53), COST: 146.98 (-0.36), ABBV: 64.52 (+0.91), MMP: 81.26 (+0.05), REGN: 472.63 (+9.41), CSCO: 28.62 (-0.07), URI: 95.79 (-2.11), ROVI: 19.46 (+0.10), AVP: 8.81 (-0.07), KR: 70.39 (-1.44), FB: 84.63 (+1.01), IP: 53.04 (+0.52), PFE: 34.93 (+0.04), DIS: 107.94 (+0.26), COP: 67.88 (-0.14), AMGN: 169.10 (+0.64), WFC: 54.67 (+0.39), DENN: 11.51 (-0.06), CELG: 115.54 (+0.72), WWAV: 45.54 (-0.56), ISIS: 66.26 (-0.03), FPRX: 24.07 (-0.85)

Weakness Seen in Five Prime Therapeutics (FPRX) Estimates: Should You Stay Away? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 25, 7:43AM CDT
Five Prime Therapeutics has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.
ACOR: 33.34 (-1.33), FPRX: 24.07 (-0.85)

Vaccinex Signs Multi-Target Antibody Discovery Deal With Five Prime Therapeutics
GlobeNewswire - Thu Mar 19, 12:30PM CDT
Vaccinex, Inc. announced today that the company has entered into a multi-target collaboration agreement with Five Prime Therapeutics, Inc. to utilize Vaccinex's ActivMAb(R) antibody discovery platform for the discovery of monoclonal antibodies against novel targets identified by Five Prime's proprietary discovery platform.
FPRX: 24.07 (-0.85)

Five Prime ups revenues 39% in FY14
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 8:08AM CDT

FPRX: 24.07 (-0.85)

Five Prime Therapeutics' (FPRX) CEO Rusty Williams on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 17, 9:25PM CDT

FPRX: 24.07 (-0.85)

Five Prime Therapeutics posts 4Q loss
Automated Insights - Tue Mar 17, 3:46PM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Five Prime Therapeutics Inc. (FPRX) on Tuesday reported a loss of $11.8 million in its fourth quarter.
FPRX: 24.07 (-0.85)

Five Prime Therapeutics misses by $0.45, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 3:07PM CDT

FPRX: 24.07 (-0.85)

Five Prime Therapeutics Announces Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Tue Mar 17, 3:05PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2014.
BMY: 66.60 (-0.21), FPRX: 24.07 (-0.85)

Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2014 Financial Results and Host Conference Call on March 17
GlobeNewswire - Tue Mar 10, 3:05PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, will report its fourth quarter and full year 2014 financial results on Tuesday, March 17, 2015, after the U.S. financial markets close. Five Prime will host a conference call and live audio webcast on Tuesday, March 17, 2015 at 5:00 p.m. (ET)/2:00 p.m. (PT) to discuss the company's financial results and provide a general business update.
FPRX: 24.07 (-0.85)

Five Prime Therapeutics to Present at the RBC Capital Markets 2015 Healthcare Conference
GlobeNewswire - Wed Feb 18, 3:05PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Aron Knickerbocker, Chief Business Officer, will present at the RBC Capital Markets 2015 Healthcare Conference on Wednesday, February 25, 2015 at 10:30 AM Eastern Standard Time. The conference will take place at the New York Palace Hotel in New York City.
FPRX: 24.07 (-0.85)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

University of Phoenix Grads Shine in Job Readiness

University of Phoenix Graduates Proving Their Worth Dive straight into the world of University of Phoenix grads, and you're looking at some folks who seem to have the workplace game figured out. A fresh Harris Poll, done on behalf of the University itself, paints a rosy picture of these graduates from the eyes of those who actually supervise them. Turns out, managers are...

Texas A&M-San Antonio's Research Expansion Momentum

Texas A&M-San Antonio's Rising Research Ambitions A rainy day in San Antonio and Texas A&M University-San Antonio seems to have set the stage for more than just another semester of record enrollment. They’ve just rolled in with an exhilarating $8 million in external grants this fiscal year, more than doubling last year’s haul of $3.6 million, in a bid to push their...

EPR Fireworks, Schedule2.IT Enhance EMS Integration

Joining Forces for Effective EMS Management In a move that could shake up emergency medical services, EPR Fireworks has teamed up with Schedule2.IT to amp up integration. This Florida-based partnership is all about breaking down those bureaucratic firewalls between patient care and controlled substances tracking. They’re pushing for a seamless workflow, where crucial...

Haystack MRD Shines in Colorectal Cancer Trials

A New Dawn in Cancer Detection Just when you think you've seen it all in cancer diagnostics, Haystack MRD® pops up like a fresh tulip in spring. And listen, this ain't just fluff—the results from the DYNAMIC trials are a pretty compelling love letter to the power of liquid biopsy. With 100% specificity and sensitivity hitting a whopping 83.3% over five years, it’s...

Crucial Insights for South GA Home Insurance Choices

Understanding the Insurance Jargon Here we go again, dealing with insurance gobbledygook that’s about as clear as mud to most of us. Homeowners in South Georgia are being urged to pay attention to the differences between replacement cost and actual cash value in their insurance policies. This ain't just legalese, folks—it's your protection when disaster strikes in our...

Neutonic Sets Sights on U.S. with Walmart Expansion

Neutonic Embarks on Major Expansion with Walmart Well, here we go. Neutonic is stepping up to the big leagues by planting its flag in nearly 1,000 Walmart stores across the U.S. This move lands them right in the thrumming heart of Walmart's new Mood & Mind beverage set. It's about time this brand brings its functional beverages to American shoppers already drained by...

Local Expertise in Real Estate: Key to Success?

Local Market Know-How: A Seller's Best Asset So you're thinking about selling your home in North Carolina, huh? Here's a tip—get yourself a local real estate pro who knows the ins and outs of your neighborhood like the back of their hand. Michael McCollum, a prominent voice from Reidsville, NC, highlights how crucial local expertise can be in navigating the widely...

SaponiQ Reinvents Body Care with Botanical Soap Bars

Breaking Through with Simple Innovation I'll be the first to say it's not every day you hear about a soap company trying to shake things up in body care like it’s a tech startup, but here’s SaponiQ taking a wild swing at it with their lineup of botanical cleansing bars. These things are whipped up in their own U.S.-based facility using some fancy cold-process...

OSHA and NSC Forge Alliance to Prevent Worksite Tragedies

Forging Ahead With a Crucial Collaboration Ins, outs, ups, and downs—safety shouldn’t get lost in the shuffle, but it does. In steps the National Serious Injury and Fatality Prevention Alliance, a fresh partnership convened by OSHA with the National Safety Council—hop on board or get left behind mindsets. We’re talking about real, heads-down, hard-hitting actions...

Kroger, Imprint Team Up for AI-Driven Mastercard

Kroger Teams Up with Imprint for New Credit Card Kroger’s at it again, folks. They're rolling out a shiny new Mastercard, and it's not just any plastic—it’s powered by the AI-driven platform Imprint. Now, what does this mean for you and me? Well, if you're a frequent flyer at Kroger aisles, you might want to pay attention because this card’s offering point...